MMV: Medicines for Treating, Preventing & Eradicating Malaria Penny Grewal Daumerie Director, Global Access, MMV

MMV at a Glance  Public-Private Partnership  Established in 1999 by WHO/TDR and the Pharma Industry  Mandate: Discover, develop and deliver safe, effective and affordable antimalarials to treat and protect people most at risk of malaria  Diversified funding base  Swiss Foundation based in Geneva

MMV works with partners in 33 countries 3 countries 19 partners 6 countries 20 partners 14 countries 27 partners 10 countries 21 partners Over 80 academic, industry and endemic country partners More than 600 scientists, clinicians, public health experts

Global Malaria Portfolio- Q MMV is the main driver for antimalarial R&D (50 projects) RegistrationLead OptPhase IIPhase IIIPreclinicalPhase IDiscovery ResearchTranslationalDevelopment Coartem®-D Eurartesim™ Pyramax® Isoquine Ozonides MK 4815 Pyridone Novartis 9 projects GSK 3 projects Others 6 projects Blue AQ Others 53 projects SAR Trioxanes Artesunate Ferroquine Fosmidomycin Azithromycin Others 1 project Azithromycin chloroquine Amodiaquine Artesunate Mefloquine Artesunate DHODH DHFR NITD Immucillins Einstein Macrolides GSK Pyridones GSK DHFR Thailand Nat Product NITD 5 projects Broad/Genzyme Launch Arterolane PQP Artemifone SAR97276 Choline Non-MMV projects AQ13 Immtech Tafenoquine IV artesunate